✦ LIBER ✦

P-180 Final report of an open-label extension (OLE) study of romiplostim in MDS with a focus on patients with prolonged treatment

✍ Scribed by Fenaux, P.; Kantarjian, H.; Muus, P.; Lyons, R.M.; Larson, R.A.; Sekeres, M.A.; Becker, P.S.; Jia, C.; Yang, A.S.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A long-term, open-label extension study

✍ Finn, William F.; Joy, Melanie S. 📂 Article 📅 2005 🏛 Informa plc 🌐 English ⚖ 493 KB

P.3.d.062 An open-label extension study

✍ Mattingly, G.; Tocco, M.; Cucchiaro, J.; Xu, J.; Pikalov, A.; Loebel, A. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 58 KB

P.5.a.006 Long-term safety and tolerabil

✍ S. Bakchine; M. Rainer 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 55 KB

9209 Safety of romiplostim for treatment

✍ Fanale, M.; Stiff, P.; Noonan, K.; McCoy, J.; Rutstein, M.; Moskowitz, C. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 52 KB

Prolonged prophylaxis with dalteparin to

✍ M. S. RASMUSSEN; L. N. JORGENSEN; P. WILLE-JØRGENSEN; J. D. NIELSEN; A. HORN; A. 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB

Open-Label Study of Pemetrexed Alone or

✍ Pasi A. Jänne; Antoinette J. Wozniak; Chandra P. Belani; Mary-Louise Keohan; Hel 📂 Article 📅 2005 🏛 CIG Media Group, LP. 🌐 English ⚖ 512 KB